Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Enanta Pharmaceuticals reports strong Q1 earnings and advances antiviral programs

Enanta Pharmaceuticals delivered solid financial performance in Q1 2023, backed by revenue from AbbVie's MAVYRET sales and a strong cash position for future operations.
The company's focus on advancing their COVID-19 program, RSV therapeutics, and antiviral research programs demonstrates a commitment to addressing critical medical challenges.
While Enanta faces challenges in clinical development and market competition, opportunities in expanding their antiviral portfolio and presenting upcoming data offer avenues for growth.

Enanta Pharmaceuticals excels in COVID-19 treatment pipeline expansion

Enanta Pharmaceuticals showcased positive outcomes from the Phase 2 study of EDP-235 for COVID-19, emphasizing safety and symptom improvement.
The company's diversified pipeline, financial flexibility enhancement, and proactive strategic planning reflect a robust operational framework.
Challenges include demonstrating direct antiviral effects of EDP-235 and addressing regulatory and safety considerations in patient populations.
Opportunities lie in expanding therapeutic reach, capitalizing on market prospects, and addressing evolving healthcare needs in COVID-19 treatment.
Analyst interest in EDP-235's benefits, market opportunities, and patient population considerations underscores investor confidence and strategic relevance.

Enanta Pharmaceuticals reports positive Q3 results and growth opportunities

Enanta Pharmaceuticals showcased progress in RSV and COVID-19 programs with positive Phase I data.
Financially, the company reported revenue of $18.9 million and expects cash reserves to support operations into 2027.
Focus on high-risk patient populations and exploration of partnerships present growth opportunities.

Enanta Pharmaceuticals reports strong Q4 earnings, advances RSV program

Enanta Pharmaceuticals reported solid financial performance in Q4 2023, with a focus on cost reduction and strategic allocation of resources.
The company's RSV program progress and adjustments to prioritize key studies demonstrate a commitment to advancing its pipeline and making informed decisions.
While facing challenges in clinical trial recruitment and navigating the impact of COVID, Enanta remains focused on exploring new therapeutic avenues and leveraging opportunities for growth.
Ongoing discussions with the FDA, progress in key studies, and strategic decision-making underscore Enanta's efforts to drive innovation and address medical needs.

Enanta Pharmaceuticals reports Q1 revenue, progresses in RSV and immunology

Enanta Pharmaceuticals is progressing well in RSV and immunology programs, with a focus on oral treatments for respiratory syncytial virus and chronic spontaneous urticaria.
Financially, the company reported total revenue of $18 million, decreased R&D expenses, and ended the quarter with $337 million in cash and marketable securities.
Challenges include ongoing financial losses, the need for successful Phase 2 studies, and developing a best-in-disease oral KIT inhibitor.
Opportunities lie in market demand for oral treatments, entering markets with high unmet medical needs, and developing compounds with selectivity against KIT kinase.

Enanta Pharmaceuticals reports solid Q2 earnings amidst pipeline advancements

Enanta Pharmaceuticals is strategically positioned with a focus on virology and immunology, strong financial stability, and promising pipeline candidates like zelicapavir and EDP-323.
While facing challenges such as patent litigation, the company's emphasis on innovation and potential expansion into new indications presents exciting growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the eld

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used for its RSV and hMPV programs, will be presented during the 12th International RSV Symposium at ICC Belfast in Northern Ireland, United Kingdom. An oral presentation and poster highlight the pre

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data related to its respiratory syncytial virus (RSV) program, as well as new virology methods used for its RSV and human metapneumovirus (hMPV) programs, will be presented at the 12th International RSV Symposium being held on September 29 – October 2, 2022 at

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington, DC. Oral Presentation Date: Friday, October 21, 2022 Time: 12:1

New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September: Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022 Baird Global Healthcare Conference: Fireside Chat at 9:40

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - President, CEO & Director Paul Mellett - SVP, Finance & Administration & CFO Tara Kieffer - SVP, New Product Strategy & Development Conference Call Participants Douglas Buchanan - JMP Securities Brian Skorney - Robert W. Baird & Co. Hannah Adeoye - JPMorgan Chase & Co. Roanna Ruiz - SVB Securities Operator Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter 2022 Financial Results Conference Call.

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2022. “Currently approved COVID-19 vaccines offer less protection against infection from new SARS-CoV-2 variants, especially BA.5, and we continue to see the need for an easily accessible, once-daily oral antiviral for t

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, re

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, includ

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the '953 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmat

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta's internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Int

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June: Jefferies Healthcare Conference: Fireside Chat at 9:00 a.m. ET on June 9, 2022 JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on Ju

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for RSVP, its Phase 2b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the pr

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Jennifer Viera - Director of IR & Corporate Communications Jay Luly - President and CEO Paul Mellett - CFO Nathalie Adda - Consultant Tara Kieffer - SVP, New Product Strategy & Development Conference Call Participants Luke Herrmann - Robert W. Baird Brian Abrahams - RBC Capital Markets Swapnil Malekar - Piper Sandler Akash Tewari - Jefferies Roy Buchanan - JMP Securities Hannah Adeoye - JPMorgan Jay Olson - Oppenheimer Zegbeh Jallah - ROTH Capital Partners Roanna Ruiz - SVB Leerink Operator Good afternoon.

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2022 Results - Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2022. “We had a strong start to 2022, making meaningful strides to advance our leadership in the development of therapeutics for viral infections with important progress in our broad pipeline, most notably in our clini

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, includi

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Receives Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

News for Enanta Pharmaceuticals Stock (ENTA)